AI-enabled drug transactions increasingly turn on more than patents and scientific merit. This article examines data provenance, IP ownership, collaboration terms, and model dependencies that can affect diligence, valuation, and deal readiness.

In AI-enabled drug discovery, enterprise value depends on more than the pipeline. Data ownership, licensing terms, model improvements, and platform dependencies can shape IP strategy, diligence, and commercialization.

As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

Strong patents aren't always enough. In biotech and pharma, success hinges on how well your IP tells a story. Learn why great inventions fail in the market, how to craft a compelling IP narrative, and what investors and licensing partners really want to hear. Discover Hylton-Rodic Law’s approach to building winning patent strategies.